A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine functions by activating the mother’s body’s defences to generate protective antibodies, which are then transferred to the foetus through the placenta. This maternal immunity offers newborns with instant defence from the moment of birth, exactly when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence indicating that a fortnight’s interval is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent protection when vaccinated 4 weeks before birth
- Maternal antibodies transferred through placenta safeguard newborns from birth
- Coverage achievable with two-week gap before early delivery
- Vaccination during third trimester still provides significant protection for infants
Compelling evidence from current research
The effectiveness of the RSV vaccine administered during pregnancy has been established through a comprehensive study conducted across England, analysing data from nearly 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that half-year window, providing strong and reliable information of the vaccine’s practical effectiveness. The study’s conclusions have been endorsed by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The scope of this study offers healthcare professionals and parents-to-be with trust in the vaccine’s established performance across diverse populations and circumstances.
The results present a striking picture of the vaccine’s protective power. More than 4,500 babies were treated in hospital with RSV during the study period, with the great majority being infants whose mothers had not received the vaccination. This marked difference emphasises the vaccine’s vital importance in protecting against serious illness in newborns. The decrease in hospital admissions above 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish direct comparisons of RSV infection levels and hospital admissions. The substantial sample size and thorough nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than individual cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to establish the minimum time required between vaccination and birth for optimal protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology measured actual clinical results rather than controlled laboratory conditions, providing practical evidence of how the vaccine works when given across diverse clinical settings and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the dangers
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during busier periods.
The infection triggers deep inflammation in the lungs and airways, making it extremely challenging for vulnerable newborns to breathe and feed effectively. Parents often witness their babies fighting for breath, their chests rising whilst they work to get sufficient oxygen into their compromised lungs. Whilst most newborns improve through palliative treatment, a small but significant group succumb from RSV complications annually, making immunisation programmes a essential public health priority for protecting the most vulnerable and youngest members of society.
- RSV triggers lung inflammation, causing severe breathing difficulties in infants
- Approximately half of newborns catch the virus in their first few months of life
- Symptoms span from minor cold-like symptoms to serious chest infections that threaten life requiring hospitalisation
- Over 20,000 UK babies require serious hospital care for RSV annually
- Few babies succumb to RSV complications each year in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme launched in 2024, health officials have stressed the value of pregnant women receiving their jab at the best time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing is crucial for guaranteeing newborns benefit from the strongest possible immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery delivers nearly 85% protection, experts encourage women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to maximise the antibodies transferred to their babies through the placenta.
The guidance from health authorities remains clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has reassured pregnant women that protection remains still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those giving birth ahead of schedule. This flexible approach acknowledges the practical demands of pregnancy whilst ensuring strong safeguarding for at-risk infants during their most critical early months when RSV poses the greatest risk of serious illness.
Regional variations in immunisation
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others continue working to increase awareness and availability of the jab. These geographical variations reflect variations in healthcare infrastructure, communication strategies, and community involvement initiatives, though the national data demonstrates consistently strong protection irrespective of geographical location.
- NHS trusts rolling out multiple messaging strategies to engage with women during pregnancy
- Geographic variations in immunisation take-up in different parts of England necessitate strategic intervention
- Local healthcare systems modifying schemes to align with community needs and circumstances
Practical implications and parent viewpoints
The vaccine’s impressive effectiveness translates into real advantages for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the introduction of this protective measure, the 80% reduction in admissions equates to thousands of infants protected against serious illness. Parents no longer face the troubling prospect of seeing their babies struggle for breath or labour to feed, symptoms that mark severe RSV infections. The vaccine has markedly changed the landscape of neonatal breathing health, offering expectant mothers a preventative option to shield their most at-risk babies during those vital initial period.
For families like that of Malachi, whose serious RSV infection caused severe brain damage, the vaccine’s availability carries profound emotional significance. His mother’s promotion of the jab underscores the transformative consequences that vaccine-preventable disease can inflict on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such grave complications—hospitalisation, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to women in pregnancy in their final trimester, changing what was once an predictable seasonal threat into a controllable health concern.